Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seclidemstat and Azacitidine in MDS and CMML
NCT04734990Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2021
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Seclidemstat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2021; status: active, not recruiting.
02
Drugs
Seclidemstat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04734990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04734990.